Prevalence of Other Cancers in Ovarian Cancer Patients
Article Sidebar
Main Article Content
Abstract
Objective: To study the prevalence of other cancers in patients with ovarian cancer and history of cancer in their families
Methods: The patients with cancers of ovary who were treated in the institution during Jan 1, 1997 to December 31, 2016 were identified. Inclusion criteria were patients with epithelial ovarian cancer who had surgery in the institution or elsewhere with available clinical and pathological data. Exclusion criteria were patients with metastatic cancer to ovaries or had incomplete data. Data collected were: age at diagnosis, histopathology, grade, and stage of ovarian cancer, site and histopathology of other cancer, and timing of occurrence in relation to ovarian cancer
Results: During the study period, 1004 patients with ovarian cancer were identified. We excluded 347 patients who had non-epithelial type of cancer (130 patients), had incomplete or unverified data (217 patients). A total of 657 patients who met inclusion criteria were included in the study. Mean age of the patients was 51.4 ± 12.5 years. Serous carcinoma was the most common histopathology (27.4 %). Nearly half (45.4%) had tumor grade 3 and slightly more than half (52.5%) delete full stop here had early stage (FIGO stage I-II). We found 32 patients (4.9%) had other types of cancer which were synchronous in 24 patients (75.0%). The most common type of other cancer was endometrial cancer (62.5%) followed by colon and cervix in equal frequency (6.3% each). Family history of cancer among these patients was not available in almost all cases.
Conclusion: The prevalence of other cancers in patients with cancers of ovary was 4.9%. The most common was endometrial cancer.
Article Details
References
2. Persson I, Weiderpass E, Bergkvist L, Bergstrom R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 1999;10:253-60.
3. Soliman PT, Wu D, Tortolero-Luna G, Schmeler KM, Slomovitz BM, Bray MS, et al. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer 2006;106: 2376-81.
4. Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol 2004;94:256-66.
5. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003 May;72(5):1117-30. PubMed PMID: 12677558. Pubmed Central PMCID: 1180265.
6. King MC, Marks JH, Mandell JB, New York Breast Cancer Study G. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302(5645):643-6.
7. Meyer LA, Broaddus RR, Lu KH. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control 2009;16(1):14-22.
8. Erikci AA, Ozturk A, Tekgunduz E, et al. Acute myeloid leukemia complicatng multiple myeloma: a case successfully treated with etoposide, thioguanine, and cytarabine. Clin Lymphoma Myeloma 2009; 9: 14-15.
9. Escobar PA, Smith MT, Vasishta A, et al. Leukemia-specigic chromosome damage detected by comet with florescence in situ hybridisation (comet-FISH). Mutagenesis 2007; 22: 321-7.
10. AIRTUM Working Group. Italian cancer figures, report 2013: Multiple tumours. Epidemiol Prev 2013;37(4-5 Suppl 1):1-152.
11. Demandante CG, Troyer DA, Miles TP (2003). Multiple primary malignant neoplasms: case report and a comprehensive review of the literatüre. Am J Clin Oncol 2003; 26: 79-83.
12. Axelrod JH, Fruchter R, Boyce JG. Multiple primaries among gynecologic malignancies. Gynecol Oncol 1984;18(3):359-72.
13. Arpaci E, Tokluoglu S, Yetigyigit T, Alkis N. Multiple primary malignancies--a retrospective analysis at a single center in Turkey. Asian Pac J Cancer Prev 2013;14(2):769-73.
14. Kwast AB, Liu L, Roukema JA, Voogd AC, Jobsen JJ, Coebergh JW, et al. Increased risks of third primary cancers of non-breast origin among women with bilateral breast cancer. Br J Cancer 2012;107(3):549-55.
15. Whynott RM1, Manahan KJ, Geisler JP. Breast cancer is common in women with ovarian malignant mixed mullerian yumors. Am J Clin Oncol 2016 Jan 11. [Epub ahead of print]
16. Sisti A, Tassinari J, Nisi G, Grimaldi L, Sisti G, DI Tommaso M, Fambrini M. Synchronous and metachronous malignancies after malignant struma ovarii in the SEER database. In Vivo 2016;30(5):713-6.
17. Tangjitgamol S, Khunnarong J, Srijaipracharoen S. Synchronous and metachronous malignancy in endometrial cancer patients treated in a tertiary care center of Thailand. J Gynecol Oncol 2015; 26(4): 293-302.
18. Suzuki T, Takahashi H, Yao K, et al. Multiple primary malignancies in the head and neck: a clinical review of 121 patients. Acta Otolaryngol 2002; 547: 88-92.
19. Mariani A, Cha SS, Bergstralh EJ, Boardman LA, Dowdy SC, Keeney GL, et al. Referral and ascertainment bias in patients with synchronous and metachronous endometrial malignancy. Eur J Gynaecol Oncol 2010;31(1):5-9